Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668]

Bibliographic Details
Main Authors:	Tianyao Lei, Tianwei Xu, Niu Zhang, Xiaoteng Zou, Ziyue Kong, Chenchen Wei, Zhaoxia Wang
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	Pharmacological Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661823002785

Internet